An Exploratory, Multicenter, Placebo-controlled, Randomized, Double-blind Study to Investigate the Antidepressant Mechanism-of-action of JNJ-42847922 in Subjects With Major Depressive Disorder
Phase of Trial: Phase I
Latest Information Update: 21 May 2019
Price : $35 *
At a glance
- Drugs Seltorexant (Primary)
- Indications Major depressive disorder
- Focus Therapeutic Use
- Sponsors Janssen Research & Development
- 16 May 2019 Status changed from active, no longer recruiting to completed.
- 17 Apr 2019 Planned End Date changed from 3 Jun 2019 to 29 Apr 2019.
- 17 Apr 2019 Planned primary completion date changed from 28 Feb 2019 to 29 Apr 2019.